AbbVie Inc. (ABBV)

91.54
0.37 0.40
NYSE : Health Technology
Prev Close 91.91
Open 91.67
Day Low/High 91.35 / 92.20
52 Wk Low/High 85.24 / 125.86
Volume 350.26K
Avg Volume 5.60M
Exchange NYSE
Shares Outstanding 1.51B
Market Cap 135.04B
EPS 3.30
P/E Ratio 22.07
Div & Yield 3.84 (3.61%)

Latest News

AbbVie Reinforces Leadership In Gastroenterology With New Data Showcasing Research Advancements Across Robust Portfolio At United European Gastroenterology (UEG) Week 2018

AbbVie Reinforces Leadership In Gastroenterology With New Data Showcasing Research Advancements Across Robust Portfolio At United European Gastroenterology (UEG) Week 2018

- Eleven presentations of HUMIRA® (adalimumab) and pipeline data showcase breadth and depth of robust gastroenterology portfolio

AbbVie To Present New Data For Upadacitinib And HUMIRA® (adalimumab) At The 2018 ACR/ARHP Annual Meeting

AbbVie To Present New Data For Upadacitinib And HUMIRA® (adalimumab) At The 2018 ACR/ARHP Annual Meeting

- Oral presentations include three of the five pivotal studies from AbbVie's SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against Abbvie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Clorox, Sirius XM Radio, New Relic, AbbVie, ShotSpotter and more.

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

Jim Cramer asks if the Fed is trying so hard to cool the economy that it could crush wage growth.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/14/2018 settlement date, and AbbVie Inc is one of the most shorted stocks of the Russell 3000, based on 7.73 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

RM LAW Announces Class Action Lawsuit Against AbbVie Inc.

BERWYN, Pa., Sept.

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors Of Deadline In Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc.

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm

NEW YORK, Sept. 24, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AbbVie Inc.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AbbVie Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc.

AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV

AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV

NEW YORK, Sept. 23, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie Inc.

Hagens Berman Alerts Investors In AbbVie Inc. (ABBV) To The Firm's Investigation Of Possible Humira-Related Health Insurance Fraud And Disclosure Violations

Hagens Berman Alerts Investors In AbbVie Inc. (ABBV) To The Firm's Investigation Of Possible Humira-Related Health Insurance Fraud And Disclosure Violations

SAN FRANCISCO, Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against AbbVie Inc. - ABBV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc.

AbbVie Receives Positive CHMP Opinion For A Novel, Chemotherapy-free Combination Of VENCLYXTO® (venetoclax Tablets) With Rituximab As A Treatment With A Fixed Duration For Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

AbbVie Receives Positive CHMP Opinion For A Novel, Chemotherapy-free Combination Of VENCLYXTO® (venetoclax Tablets) With Rituximab As A Treatment With A Fixed Duration For Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

AbbVie Investigation: Bernstein Liebhard LLP Announces Investigation Of AbbVie Inc. - ABBV

NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc.

Investor Alert: Kaplan Fox Investigates AbbVie Inc.

Investor Alert: Kaplan Fox Investigates AbbVie Inc.

NEW YORK, Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

AbbVie To Host Third-Quarter 2018 Earnings Conference Call

AbbVie To Host Third-Quarter 2018 Earnings Conference Call

NORTH CHICAGO, Ill., Sept.

The New #66 Most Shorted S&P 500 Component: AbbVie

The New #66 Most Shorted S&P 500 Component: AbbVie

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

AbbVie Presents Upadacitinib Longer-Term (32-Week) And Patient-Reported Outcomes Data From Phase 2b Atopic Dermatitis Study At 27th European Academy Of Dermatology And Venereology (EADV) Congress

AbbVie Presents Upadacitinib Longer-Term (32-Week) And Patient-Reported Outcomes Data From Phase 2b Atopic Dermatitis Study At 27th European Academy Of Dermatology And Venereology (EADV) Congress

- Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo[1]

AbbVie Announces Patient-Reported Outcomes Data From Three Pivotal Phase 3 Studies Of Risankizumab, Showing Significant Improvements In Health-Related Quality Of Life For Patients With Psoriasis

AbbVie Announces Patient-Reported Outcomes Data From Three Pivotal Phase 3 Studies Of Risankizumab, Showing Significant Improvements In Health-Related Quality Of Life For Patients With Psoriasis

- Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year (52 weeks) compared to ustekinumab[1]

Minimal Residual Disease Negativity Data, A Measure Of Undetectable Disease, Added To VENCLEXTA® (venetoclax Tablets) Label

Minimal Residual Disease Negativity Data, A Measure Of Undetectable Disease, Added To VENCLEXTA® (venetoclax Tablets) Label

- Minimal residual disease (MRD)-negativity is defined as having disease at a threshold of less than one chronic lymphocytic leukemia (CLL) cell per 10,000 lymphocytes in the blood or bone marrow[1]

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

TheStreet Quant Rating: B- (Buy)